The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | DW-MRI and serum biomarkers to assess tumor burden and bone loss in multiple myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the results of a study investigating the accuracy of the diffusion-weighted magnetic resonance imaging (DW-MRI)-based myeloma response assessment and diagnosis system (MY-RADS) response assessment category (RAC) scoring to assess therapy response in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, and multiple myeloma. Overall, the study confirmed the validity of the DW-MRI-based MY-RADS RAC tool to assess therapy response, and identified a potential serum biomarker to characterize bone status in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
